Import Alerts: How the FDA Blocks Drugs from Non-Compliant Manufacturers

The U.S. Food and Drug Administration (FDA) doesn’t wait for a single bad batch of medicine to hit pharmacy shelves before acting. Instead, it uses a powerful, automated system called Import Alerts to stop entire shipments from manufacturers with a history of violations. This isn’t a slow, paperwork-heavy process-it’s a real-time enforcement tool that blocks drugs at the border before they even get near consumers. Since September 2025, this system has been sharpened dramatically with the launch of Import Alert 66-80, targeting active pharmaceutical ingredients (APIs) for weight-loss drugs like semaglutide and tirzepatide. If your facility isn’t on the Green List, your shipment gets automatically detained. No inspection. No warning. Just stopped.

How Import Alerts Work: The Green, Yellow, and Red System

The FDA’s Import Alert system runs on a color-coded tier structure. It’s simple: Green means you’re cleared. Yellow means you’re under watch. Red means you’re blocked. There’s no gray area. Manufacturers on the Green List-those with proven, documented compliance-see nearly 99.2% of their shipments pass through U.S. customs without delay. Those not on the list? Around 98.7% of their shipments get refused on the spot.

This isn’t random. The FDA’s PREDICT algorithm, which powers this system, scans over 150 data points: past inspection results, refusal rates, facility history, even the track record of the importer. If a manufacturer has had three failed inspections in the last year, or if their Certificates of Analysis (CoA) keep being flagged as fake, PREDICT flags them. The system then auto-detects future shipments from that source and holds them under Detention Without Physical Examination (DWPE). That means customs agents don’t even open the box-they just reject it based on the data.

The Green List was introduced in September 2025 specifically to cut through the chaos of the GLP-1 drug boom. With demand for semaglutide and tirzepatide skyrocketing, unapproved versions flooded the market. Many came from facilities with no real quality control. The FDA’s response? Not just to warn-but to shut the door. Now, if you’re not on the Green List, your shipment gets held at any of the 328 U.S. ports of entry.

What Gets You on the Red List

Being placed on the Red List isn’t about one mistake. It’s about patterns. The FDA looks for:

• Repeated failures in facility inspections
• False or incomplete Certificates of Analysis
• Missing or falsified batch records
• Raw material traceability gaps
• Failure to correct violations after a warning letter

In the September 2025 GLP-1 alert, 73 out of 89 affected facilities were in India. Why? Because many Indian API manufacturers had been exporting bulk ingredients without FDA oversight, relying on loose documentation and third-party audits that didn’t meet U.S. standards. One manufacturer on the FDA Compliance subreddit reported losing $1.2 million in a single shipment-even though they had ISO 9001 certification-because their auditor wasn’t FDA-recognized. That’s the reality: international certifications don’t cut it. Only FDA-approved audit trails do.

The consequences are brutal. Refused shipments must be destroyed or shipped out of the U.S. within 90 days. If you don’t comply, you face liquidated damages up to three times the value of the goods. For a $900,000 shipment, that’s over $2.7 million in penalties. And it’s not just the money-it’s the time. It takes an average of 11.7 months to get off the Red List, even if you fix everything.

Why the Green List Is the Only Path Forward

Getting on the Green List isn’t easy. It requires:

1. A full FDA inspection of your facility (minimum 5 days)
2. A root cause analysis with a detailed Corrective and Preventive Action (CAPA) plan
3. Three consecutive shipments that pass inspection without issue
4. Executive certification that your quality system is fully compliant

But the real barrier is documentation. According to Registrar Corp’s October 2025 data, 41.7% of rejected shipments failed because their CoAs didn’t match FDA format. Another 33.8% were missing master production records. And 28.5% couldn’t prove where their raw materials came from-beyond their second-tier supplier.

To succeed, companies now need:

• Third-party audits from FDA-recognized auditors (cost: $45,000-$68,000)
• Stability testing across three temperature zones (2-8°C, 25°C/60% RH, 40°C/75% RH)
• Blockchain traceability systems to track each batch from raw material to finished product

Pfizer, for example, spent millions deploying the MediLedger blockchain network across 17 API suppliers. Their Green List acceptance rate jumped to 99.8%. That’s not luck-that’s infrastructure.

Who’s Being Hit the Hardest

The impact isn’t evenly distributed. Indian manufacturers are bearing the brunt. Of the 89 facilities affected by the GLP-1 import alert, 82% are in India. The Indian Pharmaceutical Alliance estimates 28,500 jobs are at risk. Meanwhile, Chinese manufacturers, who had been quietly filling the gap, now face new rules too. Starting January 1, 2026, China’s NMPA will require all API exporters to meet FDA-equivalent certification standards just to ship to the U.S.

In Europe, the EMA still relies on random physical inspections of 10-15% of high-risk shipments. The FDA’s DWPE system cuts inspection time by 78%. But it’s not perfect. A November 2025 study found the FDA’s system has a 17% false positive rate-meaning some clean shipments get caught in the net because of paperwork errors. That’s why the FDA quietly added a new expedited Green List pathway in November 2025: if you use an FDA-recognized auditor, your application can be approved in 45 days instead of 90.

What Happens When You Can’t Get On the List

Some companies are cutting corners. ProPublica’s investigation found that since 2013, 157 products received enforcement discretion exemptions-even from facilities with repeated violations. Mylan/Viatris’ endoscopy equipment was exempted 14 times. Shilpa Medicare’s diabetes meds got seven exemptions in 2024 alone. That’s not fairness-it’s inconsistency.

And it’s creating a black market. According to a Regulatory Focus interview, some firms are now paying brokers to falsify export documents so they can ship to third countries and relabel the drugs as “overseas formulations.” The FDA issued Warning Letter 541598 in October 2025 to a Singapore-based intermediary caught doing exactly that.

The result? U.S. pharmacies are seeing 14.3% price hikes on compounded GLP-1 formulations. Patients are paying more. And the supply chain is tightening around just a few compliant manufacturers.

The Future: It’s Getting Bigger

The GLP-1 alert was just the start. In November 2025, FDA Commissioner Dr. Robert Califf announced the system will expand to all high-risk biologics starting in Q1 2026-beginning with monoclonal antibodies. That means drugs for cancer, autoimmune diseases, and rare conditions will soon face the same scrutiny.

By 2027, McKinsey predicts 65-75% of global API manufacturers will need to spend $500,000 to $2 million upgrading their compliance systems to stay in the U.S. market. The days of shipping APIs with a PDF and a prayer are over. The new standard is transparency: real-time data, blockchain traceability, verified audits, and full facility accountability.

If you’re a manufacturer, your choice is clear: invest in compliance or lose access to the world’s largest pharmaceutical market. If you’re a pharmacy, hospital, or patient-this system is designed to keep unsafe drugs out. It’s not perfect. But right now, it’s the only thing standing between you and a batch of medicine that could be contaminated, underdosed, or worse.